Novo Nordisk has come under pressure after a prolonged slide in the share price, and the key issue now is whether the current valuation still lines up with what its earnings can reasonably support. With the stock well off its highs despite regular headlines about obesity drugs, AI partnerships and new therapies, investors are asking if the earnings story and the price tag still match. Over the past 3 years the share price has fallen 51.9%, which puts the spotlight squarely on whether the current market value is still in step with the earnings power of the business.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.